Life Sciences & Healthcare
In a dynamic environment where changing regulatory requirements, long product cycles, complex intellectual property rights and cost pressure on healthcare pose constant challenges for our clients, we offer you access to our extensive team of savvy experts. Not only are they legally qualified; they also have a deep understanding of the relevant technical and business-related issues in the life sciences and healthcare sectors.
Life Sciences is a key consulting area for our firm, where we have special expertise and proven track record, providing you with comprehensive support with pharmaceuticals, biotech, healthcare, medtech and digital health.
Areas of Expertise
Our specialists can advise you in the following areas in particular:
- Developing intellectual property strategies, patent management and exploitation of intellectual property rights, supplementary protection certificates and extensions of paediatric rights; freedom-to-operate investigations;
- National and cross-border M&A and private equity transactions and financing for pharmaceutical, biotech, healthcare and medtech companies as well as structuring and implementing joint ventures and other cooperation agreements;
- Hospital financing and cooperations;
- Distribution and supply agreements, cooperation agreements, license agreements, manufacturing agreements, research and development agreements, employee invention agreements;
- Patent litigation (infringement proceedings, invalidity proceedings, assignment and ownership disputes, licensing disputes);
- Other commercial arbitration and litigation in the field of life sciences and health care;
- Regulatory advice and compliance regarding the Therapeutic Products Act (regulatory data protection, advice on pharmaceutical products, cooperations with HCPs and HCOs etc.);
- Advertising law regarding therapeutic products, trademark law and other labelling issues regarding pharmaceuticals, biotech and medtech;
- Pricing of therapeutic products and representation before the Federal Office of Public Health
- Competition law advice (price differentiation, distribution channel planning etc.);
- E-health, data management, data protection strategies, advice in connection with digital business ideas and online platforms;
- Outsourcing projects;
- Product recall procedures
Team
- Renato Bucher
- Lukas Bühlmann
- Ulrike Ciesla
- Frédéric Cottier
- Markus Frank Huber
- L. Mattias Johnson
- Ronald Kogens
- Mark Montanari
- Michael Reinle
- Michael Ritscher
- Daniel Schoch
- Kilian Schärli
- Andrea Sieber
- Mona Stephenson
- Julie Wynne
- Nadine von Büren-Maier
- Louisa Galbraith
- Daniel Haymann
- Kevin M. Hubacher
- Simon Reuter
- Noemi Bünter
- Ada Sofie Altobelli
- Daniel Donauer
“The team is very responsive and is able to provide straightforward explanations of litigating in Switzerland”
Publications
Legal Developments in the Swiss Cannabis Market
Chambers and Partners, Expert Focus 2022 Medical Cannabis Switzerland, 15 November 2022- EN
The Legal 500 Country Comparative Guides 2022 – Switzerland: Patent Litigation
The Legal 500 Country Comparative Guides 2022, November 2022- EN
The Food, Beverage and Cosmetics Law Review: Switzerland 2022
The Law Reviews, Edition 2, 13 October 2022- EN
Normative Abgrenzung von Lebensmitteln und Arzneimitteln
Jusletter, 12. September 2022- DE
- Daniel Donauer
- Franziska Gall
Firm News
4th LESI YMC Asia-Pacific Hybrid Conference on 25 November 2022
Rechtsgutachten für Interpharma zur Schweizer Gesetzgebung über die Weiterverwendung von Gesundheitsdaten in der Schweiz
Legal Opinion for Interpharma on the Swiss Legislation on the Secondary use of health data in Switzerland
MLL Legal ranked in Who’s Who Legal Switzerland 2022
INCBA Europe @ CB EXPO on 10-11 September 2022 in Zurich
News Portal
Revision: Cannabis Regulation – New Authorization Mechanism for Dealing With Medical Cannabis
On 1 August 2022, not only the annual national holiday could be celebrated extensively in Switzerland. Particularly noteworthy is also the entry into force of the new requirements for the regulation of medical cannabis.
Cannabis was qualified as a prohibited narcotic in Switzerland until the end of summer 2022 – without further specification in relation to a medical application. Accordingly, the cultivation, importation, production, and marketing of cannabis required an exemption permit from the Federal Office of Public Health (FOPH).
More
Legal Framework for the Use of Psychedelics in Switzerland
Just in time for summer, the miniseries «How to Change Your Mind» will be launched in July on the Netflix streaming platform. In this documentary series, author Michael Pollan and Co. analyse the history and applications of psychedelic substances such as LSD, psilocybin, MDMA and mescaline. According to experts, research with psychedelics (also known as hallucinogens) or related substances will increase worldwide in the coming years. The market launch of drugs containing MDMA for post-traumatic stress disorder (PTSD) or psilocybin for the treatment of depression is expected in the next five to ten years[1]. The legal framework regarding the use of psychedelics in patients is very pragmatic in Switzerland and unique internationally. Switzerland is a leader in the research and use of psychedelics in psychiatry and is considered an innovation driver in this field. Nevertheless, the regulatory hurdles for researchers and patients are still extremely high. In this article we elaborate on the requirements under which psychedelics may be used in Switzerland today.
More
Little-Known Pitfall in Application for Paediatric Extensions or Paediatric SPCs
When filing applications for paediatric extensions and paediatric SPCs in Switzerland, it must be kept in mind that Switzerland is not a member state of the European Union and thus has a separate and independent system when it comes to the approval of medicinal products. Paediatric extensions and paediatric SPCs are only granted in Switzerland based on respective Swiss marketing authorizations issued by the competent authority Swissmedic. The relevant provisions in the Swiss Patent Act provide for some very particular conditions that the respective marketing authorizations must meet in order to serve as a basis for the grant of a paediatric extension or paediatric SPC. Those conditions are unique to Switzerland and therefore little-known abroad.
More
LexCast: Happy New Year From the MLL NexGen Incubator – Find Out What 2022 Has in Store for You!
As 2021 draws to an end MLL looks forward to 2022 and wonders what it holds. Listen to our specialists from across our offices talking about what legal trends they see coming in the year ahead.
MoreLexCast: Happy New Year From the Froriep Nexgen Incubator – Find Out What the Coming Year Has in Store for You!
As 2020 comes to an end FRORIEP looks forward to 2021 and wonders what it holds. Listen to our specialists from across our offices in London, Zurich, Madrid, Geneva and Zug talking about what they see on FRORIEP’s horizon, what they look forward to and what legal questions they hope will be clarified in the coming year.
More
